Table 4.
Uni- and multivariate analysis of factors to predict a decrease (minimally important difference) in urinary domain scores from own baseline score at 3 and 24 months
| Variables | 3 months after radiation therapy | 24 months after radiation therapy | ||||
|---|---|---|---|---|---|---|
| Analysis | ||||||
| Univariate | Multivariate | Univariate | Multivariate | |||
| P | OR (95% CI) | P | P | OR (95% CI) | P | |
| Age | 0.31 | 0.98 (0.94–1.02) | 0.22 | 0.15 | 0.97 (0.94–1.01) | 0.077 |
| Prostate volume | 0.04 | 1.02 (0.99–1.05) | 0.09 | 0.43 | 1.10 (0.99–1.03) | 0.44 |
| NCCN risk classification | ||||||
| Low | Ref | Ref | Ref | Ref | ||
| Intermediate | 0.48 | 1.31 (0.74–2.33) | 0.36 | 0.08 | 1.60 (0.93–2.76) | 0.09 |
| High | 0.88 | 0.93 (0.36–2.42) | 0.88 | 0.22 | 1.11 (0.49–2.53) | 0.81 |
| Qmax | 0.78 | 0.98 (0.94–1.01) | 0.23 | 0.85 | 0.98 (0.95–1.02) | 0.3 |
| PVR | 0.02 | 1.00 (0.99–1.01) | 0.56 | 0.18 | 1.00 (0.99–1.01) | 0.4 |
| ADT | ||||||
| No | Ref | Ref | Ref | Ref | ||
| Neo | <0.01 | 2.40 (1.38–4.2) | 0.002 | 0.04 | 1.27 (0.80–2.01) | 0.32 |
| Neo+adjuvant | 0.51 | 2.59 (1.04–6.48) | 0.041 | 0.49 | 1.75 (0.82–3.72) | 0.15 |
| Radiation therapy | ||||||
| IMRT | Ref | Ref | Ref | Ref | ||
| BT | <0.01 | 6.28 (2.94–13.4) | <0.001 | <0.01 | 2.22 (1.10–4.53) | 0.027 |
| BT + 3D-CRT | <0.01 | 12.7 (6.02–26.9) | <0.001 | <0.01 | 3.29 (1.67–6.45) | 0.001 |
| Baseline domain | 0.04 | 1.04 (1.01–1.08) | 0.033 | 0.73 | 0.97 (0.94–1.01) | 0.099 |
IMRT = intensity-modulated radiation therapy, BT = brachytherapy, 3D-CRT = 3D conformal radiation therapy, Qmax = maximum flow rate, PVR = post-void residual, ADT = androgen-deprivation therapy, Neo = neoadjuvant therapy, NCCN = National Comprehensive Cancer Network, CI = confidence interval, OR = odds ratio.